- Home
- LUXE vs ELVN Comparison
LUXE vs ELVN Comparison
Compare LUXE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUXE
- ELVN
- Stock Information
- Founded
- LUXE 1987
- ELVN 2016
- Country
- LUXE Germany
- ELVN United States
- Employees
- LUXE N/A
- ELVN N/A
- Industry
- LUXE
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- LUXE
- ELVN Health Care
- Exchange
- LUXE NYSE
- ELVN Nasdaq
- Market Cap
- LUXE 1.0B
- ELVN 927.8M
- IPO Year
- LUXE N/A
- ELVN 2020
- Fundamental
- Price
- LUXE $7.82
- ELVN $20.73
- Analyst Decision
- LUXE
- ELVN Strong Buy
- Analyst Count
- LUXE 0
- ELVN 5
- Target Price
- LUXE N/A
- ELVN $41.20
- AVG Volume (30 Days)
- LUXE 120.4K
- ELVN 734.1K
- Earning Date
- LUXE 05-14-2025
- ELVN 08-12-2025
- Dividend Yield
- LUXE N/A
- ELVN N/A
- EPS Growth
- LUXE N/A
- ELVN N/A
- EPS
- LUXE N/A
- ELVN N/A
- Revenue
- LUXE $962,367,055.00
- ELVN N/A
- Revenue This Year
- LUXE $38.43
- ELVN N/A
- Revenue Next Year
- LUXE $93.30
- ELVN N/A
- P/E Ratio
- LUXE N/A
- ELVN N/A
- Revenue Growth
- LUXE 8.74
- ELVN N/A
- 52 Week Low
- LUXE $3.22
- ELVN $13.30
- 52 Week High
- LUXE $12.50
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- LUXE N/A
- ELVN 52.36
- Support Level
- LUXE N/A
- ELVN $19.22
- Resistance Level
- LUXE N/A
- ELVN $21.90
- Average True Range (ATR)
- LUXE 0.00
- ELVN 1.46
- MACD
- LUXE 0.00
- ELVN -0.19
- Stochastic Oscillator
- LUXE 0.00
- ELVN 40.50
About LUXE LUXEXPERIENCE B.V. SPON ADS EACH RE SPON ADS EACH REP 1 ORD SHS
LuxExperience BV is the digital, multi-brand luxury group and the online shopping destination for luxury enthusiasts. The group operates a portfolio of some of the distinguished store brands in digital luxury and creates communities for luxury enthusiasts with digital and physical experiences. Its brands are MYTHERESA, NET-A-PORTER, MR PORTER, YOOX, and THE OUTNET.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.